Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients

Title: Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients

Volume: 9 Issue: 1

Author(s): Arianna Ascolani, Emanuela Balestrieri, Antonella Minutolo, Serena Mosti, Gianfranco Spalletta, Placido Bramanti, Antonio Mastino, Carlo Caltagirone and Beatrice Macchi

Affiliation:

Keywords: Alzheimer's disease, inflammation, NF-κB, MMSE, PBMCs, SuperArray, transcriptional alterations, chronic inflammatory disease, RNA isolation, neurological examination

Abstract: Diagnosis and therapeutic strategies in Alzheimers disease (AD) might greatly benefit of the present multidisciplinary approach for studying the molecular pathogenesis of the disorder. Gene expression profile at peripheral level could be a promising tool for pathogenic studies as well as for early diagnosis of AD. A dysregulated inflammatory response, as well as other systemic disorders, have been described in AD. Therefore, we investigated the expression, at peripheral level, of a number of genes involved in the inflammatory, oxidative stress and proliferative response of a well defined, small cohort of sporadic AD patients. Firstly, the mRNA expression of inflammatory, stress and proliferation/ differentiation genes were evaluated, using SuperArray, in mitogen-stimulated peripheral blood mononuclear cells (PBMC) from a group of 12 well-characterized, sporadic AD patients with various levels of dementia, by comparison with aged-matched controls. Real-time RT-PCR confirmed the trend of alteration in 16 genes out of the 36 supposed to be dysregulated in AD patients, by the preliminary screening. The expression level of the NFKB1(p105/50Kd) gene was significantly higher in AD with respect to adult age-matched controls (AA) and was related to the Mini-Mental State Examination (MMSE) score of the same patients. In addition, the expression of various NF-κB target genes and of both NF-κBp50 and NF-κBp65 DNA-binding activity were increased in PBMC from AD patients in comparison with those from AA. Our results suggest that NF-κB activation at peripheral blood cell level could be a potential new hallmark of AD progression and sustain a rationale to more deeply investigate the therapeutic potential of specific NF-κB inhibitors in AD.

Cite this article as:

Ascolani Arianna, Balestrieri Emanuela, Minutolo Antonella, Mosti Serena, Spalletta Gianfranco, Bramanti Placido, Mastino Antonio, Caltagirone Carlo and Macchi Beatrice, Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimers Disease Patients, Current Alzheimer Research 2012; 9 (1) . https://dx.doi.org/10.2174/156720512799015091